Physician profile
Sara E Shockney
NPI 1437237385
$1,509.04
in general payments reported to CMS, 2019-2025
16 companies · $667 in 2025
The $667 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $281 · 2023: $288 · 2024: $273 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $292.51 | 2023-2025 | Clareon, Total30, Dailies Total1 |
| Sun Pharmaceutical Industries INC. | $256.38 | 2022-2025 | Cequa, Xelpros |
| Tarsus Pharmaceuticals, INC. | $190.62 | 2024-2025 | Xdemvy |
| Abbvie INC. | $129.27 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Rxsight INC | $123.22 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $113.73 | 2024 | Omni Surgical System |
| New World Medical,INC. | $105.40 | 2025 | Clearpath, Via360, Streamline |
| Oyster Point Pharma, INC. | $77.12 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $54.95 | 2022 | |
| Thea Pharma INC. | $36.77 | 2023 | Iyuzeh |
| Dompe US, INC. | $29.41 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $25.26 | 2025 | Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $24.17 | 2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $17.52 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $16.51 | 2023 | Cirrus Hd-Oct |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Shockney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.